About this trial
Intraoperative hemodynamic instability (IOHI) is a common occurrence during cardiac surgery and is associated with organ hypoperfusion. However, the specific impact of IOHI on composite adverse outcomes remains unclear. This prospective cohort study aims to evaluate the association between intraoperative hemodynamic instability (defined as MAP \< 65 mmHg or vasopressor requirement) and major postoperative complications (Delirium, Acute Kidney Injury, Stroke, or Mortality) in adult patients undergoing elective cardiac surgery with cardiopulmonary bypass.
Eligibility criteria
This trial does not accept healthy volunteersQualifiers
Patients aged 18 years or older.
Scheduled for elective cardiac surgery (CABG, Valve replacement/repair, or combined procedures).
Surgery performed under cardiopulmonary bypass (CPB).
Preoperative sinus rhythm.
Disqualifiers
Emergency or salvage surgery.
Off-pump coronary artery bypass grafting.
Preoperative mechanical circulatory support (IABP, ECMO) requirement.
Pre-existing chronic renal failure requiring dialysis (HD/PD).
Trial population
Adult patients undergoing elective cardiac surgery with cardiopulmonary bypass at a tertiary care university hospital.
Trial design
Cohort
Prospective
Treatments tested in this trial
Not listed
Trial groups
Trial outcomes
Primary outcomes
Incidence of Composite Adverse Events
A composite endpoint defined as the occurrence of any of the following within 30 days post-surgery: Postoperative Delirium (assessed by CAM-ICU), Acute Kidney Injury (KDIGO criteria stage 1 or higher), Stroke (new neurological deficit confirmed by imaging), or All-cause Mortality.
Secondary outcomes
Duration of Mechanical Ventilation
Time from ICU admission to successful extubation (in hours).
Length of Hospital Stay
Total duration of hospital stay from surgery to discharge (in days)
Length of Intensive Care Unit (ICU) Stay
Time from admission to the Intensive Care Unit immediately after surgery until discharge to the ward (in days).
Sponsors and contacts
Click on the lead sponsor to view all of their trials.